Clinical trial · Observational
Detection and Pathogenesis of Novel Protein F
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
From December 6, 2019 to March 23, 2020, the research group of Qingkun Fan found a novel protein(temporarily named protein F) in heparin anticoagulant plasma of three patients with heart disease. One patient was diagnosed with multiple myeloma.However, protein F cannot be detected by serum protein electrophoresis. Preliminary studies have shown that this novel protein F have an obvious absorption peak at about 600nm. Placed at 2-8 degrees for 7 days, protein F will be isolated from heparin plasma. To the naked eye, protein F appear to be transparent jelly between the red blood cells and the plasma. The specific protein F, how it is produced, how it causes disease are still unknown. This study will explore how to detect protein F and how it is produced.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiac Disease | — | UNRESOLVED | — |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Concentration of plasma protein F content
- timeFrame
- six month
- description
- the protein F content was measured by turbidimetric assay in automatic biochemical analyzer
Secondary outcomes (1)
- measure
- Number of Participants with Multiple myeloma
- timeFrame
- 3 years
- description
- Develop or be diagnosed with multiple myeloma
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * Testing total protein and albumin * Testing routine blood test Exclusion Criteria: * high triglycerides (TG\>5.00 mmol/L) * hyperbilirubinemia (TBIL\>170 mmol/L) * fat emulsion used in past 3 days * patients with hemolytic disease * pregnant and lactating women
References
Publications (0)
Data not yet available